Skip to content

Subscribe to AcuCort's newsletter

* indicates required


Message from the CEO

“AcuCort is entering a new and exciting phase, focusing on the commercialisation of our innovative and patient-friendly oral film Zeqmelit®, for acute and severe allergic reactions, among others.”

Jonas Jönmark, CEO, AcuCort AB
February 24, 2023

We make good drugs better

AcuCort develops innovative treatments based on existing and well-documented substances in treatment areas where there is a high unmet medical need and commercial interest in new drugs that add benefits such as simplicity of administration.

Latest videos from AcuCort

Acucort – Stora Aktiedagen Stockholm 15 mars 2023

AcuCort AB

March 16, 2023 09:45

AcuCort – Bokslutskommuniké 2022

AcuCort AB

February 24, 2023 10:48